Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuland LaboratoriesNSE:NEULANDLAB -2.04%90 3-Year EBITDA Growth Rate is 29.00% as of Mar. 2026, which is 54% above its 10-year median of 18.80. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 90/100 and a GF Value™ of ₹16,214.13 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 812 Drug Manufacturers companies, Neuland Laboratories ranks better than 78.69% on this metric.
During the past 12 months, Neuland Laboratories's average EBITDA Per Share Growth Rate was 43.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 29.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 34.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 24.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Neuland Laboratories was 44.10% per year. The lowest was -18.60% per year. And the median was 18.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Neuland Laboratories 3-Year EBITDA Growth Rate Related Terms
NSE:NEULANDLAB vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 29.00% mean?
Neuland Laboratories (NSE:NEULANDLAB) has a 3-Year EBITDA Growth Rate of 29.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Neuland Laboratories and its competitors. This is 54% above median its historical median of 18.80. According to the industry distribution chart, Neuland Laboratories ranks #173 out of 812 companies in the Drug Manufacturers industry, placing it in the top 21.3%.
Is Neuland Laboratories' 3-Year EBITDA Growth Rate too high?
Neuland Laboratories' current 3-Year EBITDA Growth Rate of 29.00% is 54% above median its 10-year median of 18.80. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.75. Neuland Laboratories' value of 29.00% is 231.4% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #173 out of 812 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #173 out of 812 companies for 3-Year EBITDA Growth Rate. This places Neuland Laboratories in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.75. Neuland Laboratories' value of 29.00% is 231.4% above this benchmark. While the company's 10-year median is 18.80 vs. the industry median of 8.75, Neuland Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.75, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current 3-Year EBITDA Growth Rate of 29.00% is 231.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current 3-Year EBITDA Growth Rate is 29.00%, which is 54% above median its own 10-year median of 18.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,214.13, compared to a current price of ₹19,273.00 — trading 18.9% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 29.00%, which is 54% above median its 10-year median of 18.80 and 231.4% above the Drug Manufacturers industry median of 8.75. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current 3-Year EBITDA Growth Rate is 29.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹19,273.00 is trading 18.9% above its estimated GF Value™ of ₹16,214.13.
GuruFocus considers Neuland Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
3-Year EBITDA Growth Rate: 29.00% (54% above median its 10-year median of 18.80)
GF Value™: ₹16,214.13 vs. price of ₹19,273.00 (18.9% above fair value)
Industry Position: 231.4% above the Drug Manufacturers median (#173 of 812)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score
Get the complete analysis for NSE:NEULANDLAB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
